Fleming, Hawthorn team up to expand sales of CaloMist
ST. LOUIS Fleming Pharmaceuticals has announced a partnership with Hawthorn Pharmaceuticals to expand the sales reach of Fleming’s newly introduced drug, CaloMist. The drug, which is a once-daily Vitamin B12 nasal spray, is the first and only approved by the Food and Drug Administration to treat Vitamin B12 deficiency.
Under the agreement, Hawthorn will use its nationwide sales force to promote the product in every major metropolitan market in the U.S. The drug will be promoted as an alternative to intramuscular injections of the vitamin as the way to treat Vitamin B12 deficiency.
“We are thrilled to be working in concert with Fleming Pharmaceuticals on CaloMist” said Chris Smith, executive vice president of sales for Hawthorn Pharmaceuticals. “We know our sales force and physician relationships will bring real value and help build sales for this important new way to manage Vitamin B12 deficiency.”
The drug was released in December 2007 and is currently available by prescription.
FDA to open office in India
KOCHI The Food and Drug Administration is planning on opening an office of its agency in India, in an effort to ensure the quality of the food and drugs being imported by the U.S., according to published reports.
Health and Human Service secretary Michael Leavitt and FDA commissioner Andrew von Eschenbach are in the country presently assessing the manufacturing practices existing at drug and food processing units.
According to Leavitt, he set up the mission because, “there was a serious apprehension among the consumers in this country on the quality of food and drugs being imported.” “We are trying to ensure the quality in the entire system of supply chain, right from the seed to the last outlet from where people buy the goods,” he said.
The U.S. imports about $56 million worth of food and drug products from India.
BioDelivery works on risk management plan for dissolving fentanyl patch
RALEIGH, N.C. BioDelivery Services International is planning on developing a safety plan for its new BEMA fentanyl patch, which the Food and Drug Administration accepted for review last week, according to published reports.
In December, a public health advisory from the FDA was released following reports of life-threatening side effects and even death associated with inappropriate prescriptions or use of the patches. So, to be safe, BioDelivery has developed a Risk Minimization Action Plan, or RiskMap, for its patch, which dissolves in the mouth and is placed on the walls of the cheek, unlike other fentanyl patches, which are placed on the skin and have to be disposed of.
Fentanyl is a narcotic pain medication more powerful than morphine. It has been in use for years. The FDA first issued a public health advisory for fentanyl skin patches in July 2005 following reports of the deaths of some patients.
BioDelivery’s vice president of marketing stated that the company is more confident as to the differences between its patch and other fentanyl patches, and believes the confidence is extended to how the drug is meant to be used and how the drug is delivered in the body.